1. Home
  2. DOMO vs MSLE Comparison

DOMO vs MSLE Comparison

Compare DOMO & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$3.76

Market Cap

171.6M

Sector

Technology

ML Signal

HOLD

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$7.73

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DOMO
MSLE
Founded
2010
N/A
Country
United States
Canada
Employees
N/A
17
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
171.6M
146.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
DOMO
MSLE
Price
$3.76
$7.73
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$10.28
N/A
AVG Volume (30 Days)
1.3M
52.0K
Earning Date
05-20-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
31.92
N/A
EPS
N/A
N/A
Revenue
$318,857,000.00
N/A
Revenue This Year
$3.41
N/A
Revenue Next Year
$4.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.57
N/A
52 Week Low
$2.39
$5.50
52 Week High
$18.49
$13.39

Technical Indicators

Market Signals
Indicator
DOMO
MSLE
Relative Strength Index (RSI) 54.01 51.69
Support Level $2.39 $6.73
Resistance Level $4.11 $8.37
Average True Range (ATR) 0.31 0.75
MACD 0.06 0.14
Stochastic Oscillator 75.76 33.83

Price Performance

Historical Comparison
DOMO
MSLE

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: